China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China · Delayed Price · Currency is CNY 18.31
-0.20 (-1.08%)
Feb 13, 2026, 3:00 PM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 2.54B CNY in the quarter ending September 30, 2025, a decrease of -2.96%. This brings the company's revenue in the last twelve months to 10.95B, down -4.06% year-over-year. In the year 2024, China Resources Double-Crane Pharmaceutical had annual revenue of 11.21B, down -0.87%.
Revenue (ttm)
10.95B
Revenue Growth
-4.06%
P/S Ratio
1.73
Revenue / Employee
816.06K
Employees
13,414
Market Cap
18.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
| Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | 8.50B | -877.05M | -9.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.20B |
| Shandong Buchang Pharmaceuticals | 10.96B |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
| Tasly Pharmaceutical Group | 8.24B |
| Betta Pharmaceuticals | 3.26B |
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Walvax Biotechnology | 2.40B |